Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: Results from a prospective observational study (CAPRO)

  1. Puente, J.
  2. González-Del-Alba, A.
  3. Sala-Gonzalez, N.
  4. Méndez-Vidal, M.J.
  5. Pinto, A.
  6. Rodríguez, Á.
  7. Cuevas Sanz, J.M.
  8. Muñoz Del Toro, J.R.
  9. Useros Rodríguez, E.
  10. García García-Porrero, Á.
  11. Vázquez, S.
Revista:
BMC Cancer

ISSN: 1471-2407

Any de publicació: 2019

Volum: 19

Número: 1

Tipus: Article

DOI: 10.1186/S12885-019-5974-9 GOOGLE SCHOLAR lock_openAccés obert editor

Objectius de Desenvolupament Sostenible

Font de les dades: Scopus